跳至主要内容
临床试验/NCT00185900
NCT00185900已完成不适用

Magnesium Sulfate Versus Nifedipine for the Acute Tocolysis of Preterm Labor: A Prospective, Randomized Trial

Stanford University1 个研究点 分布在 1 个国家目标入组 192 人开始时间: 1999年4月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
192
试验地点
1
主要终点
Number of Participants With Prevention of Preterm Delivery for 48 Hours With Attainment of Uterine Quiescence

研究概览

简要总结

To compare intravenous magnesium sulfate to oral nifedipine for acute tocolysis of preterm labor

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • :- Uterine contractions and cervical change or ruptured membranes in a preterm gestation

排除标准

  • placental abruption, fetal distress, placenta previa, maternal medical contraindication to tocolysis

研究组 & 干预措施

Magnesium Sulfate

Active Comparator

Preterm labor treatment with Magnesium Sulfate.

干预措施: Magnesium Sulfate (Drug)

Nifedipine

Active Comparator

Preterm labor treatment with Nifedipine.

干预措施: Nifedipine (Drug)

结局指标

主要结局

Number of Participants With Prevention of Preterm Delivery for 48 Hours With Attainment of Uterine Quiescence

时间窗: 48 hours after administration of study medication.

Uterine quiescence defined by 12 hours of six or fewer contractions per hour and no further cervical change within 48 hours of tocolytic initiation.

次要结局

  • Serious Maternal Adverse Effect(From study enrollment until discharge from delivery hospital, up to 30 days after delivery.)
  • Gestational Age at Delivery(Until delivery, up to 42 weeks of gestation)
  • Time to Uterine Quiescence(Until delivery, up to 42 weeks of gestation)
  • Neonatal Birth Weight(Until delivery, up to 42 weeks of gestation)
  • Composite Neonatal Morbidity(From delivery until discharge from the hospital, up to 30 days of age)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Yasser Yehia El-Sayed

Principle Investigator

Stanford University

研究点 (1)

Loading locations...

相似试验